• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[乳腺癌患者中前胶原蛋白-I、胶原蛋白端肽I、癌胚抗原、CA 15-3与骨闪烁显像的比较]

[Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].

作者信息

Zissimopoulos Athanassios, Petrakis Georgios, Stellos Kappaonstantinos, Baziotis Nikolaos

机构信息

Medical School of Democritus University of Thrace, Alexandroupolis, Greece.

出版信息

Hell J Nucl Med. 2006 Jan-Apr;9(1):60-4.

PMID:16617400
Abstract

UNLABELLED

The most common metastases of breast cancer (BC) are bone metastases. Serum pro-Iota collagen peptide (PICP) and I collagen telopeptide (ICTP) levels indicate the rate of bone collagen synthesis and bone resorption respectively and therefore indicate metastatic activity in the bone. We have studied the clinical importance of serum PICP and ICTP as well as CA 15-3 and CEA and compared them to bone scintigraphy findings indicating metastases from BC. Ninety seven women of mean age 58+/-8 years with BC were examined. The diagnosis of BC was histologically confirmed. Bone metastases were diagnosed in 68 of them by bone scans performed after the intravenous injection of 925 MBq of technetium-99m methylendiphosphonate, while 29 patients were free from bone metastases. We also examined 52 women of similar age, as controls. Serum PICP, ICTP, CA 15-3 and CEA were measured in both patients and controls. Serum levels of ICTP and CA 15-3 were significantly higher in patients with BC and bone metastases compared to patients without metastases (P<0.05), while PICP and CEA were only marginally higher. A statistically significant correlation was observed between the existence of bone metastases and ICTP serum levels (P<0.05). The sensitivity of PICP, ICTP, CEA and CA 15-3 was 28.1%, 48.6%, 78%, 42% respectively and their specificity was 83.9%, 94%, 65% and 86% respectively.

IN CONCLUSION

ICTP and CA 15-3 are the most reliable markers of those studied for the diagnosis of bone metastases in BC. PICP alone or combined with ICTP were not sensitive enough. CA 15-3 showed sensitivity 78% and specificity 86%. When combining CA 15-3, ICTP and CEA the sensitivity and specificity increased to 82% and 96% accordingly.

摘要

未标注

乳腺癌(BC)最常见的转移部位是骨转移。血清前I型胶原肽(PICP)和I型胶原末端肽(ICTP)水平分别指示骨胶原合成速率和骨吸收情况,因此可反映骨转移活性。我们研究了血清PICP、ICTP以及CA 15 - 3和癌胚抗原(CEA)的临床重要性,并将它们与提示BC骨转移的骨闪烁显像结果进行比较。对97名平均年龄为58±8岁的BC女性进行了检查。BC诊断经组织学确认。其中68人通过静脉注射925 MBq的锝 - 99m亚甲基二膦酸盐后进行骨扫描诊断为骨转移,而29名患者无骨转移。我们还检查了52名年龄相仿的女性作为对照。对患者和对照者均检测了血清PICP、ICTP、CA 15 - 3和CEA。与无转移的患者相比,有骨转移的BC患者血清ICTP和CA 15 - 3水平显著更高(P<0.05),而PICP和CEA仅略高。骨转移的存在与ICTP血清水平之间存在统计学显著相关性(P<0.05)。PICP、ICTP、CEA和CA 15 - 3的敏感性分别为28.1%、48.6%、78%、42%,特异性分别为83.9%、94%、65%和86%。

结论

在研究的指标中,ICTP和CA 15 - 3是诊断BC骨转移最可靠的标志物。单独的PICP或与ICTP联合使用敏感性均不足。CA 15 - 3的敏感性为78%,特异性为86%。当联合使用CA 15 - 3、ICTP和CEA时,敏感性和特异性相应提高到82%和96%。

相似文献

1
[Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].[乳腺癌患者中前胶原蛋白-I、胶原蛋白端肽I、癌胚抗原、CA 15-3与骨闪烁显像的比较]
Hell J Nucl Med. 2006 Jan-Apr;9(1):60-4.
2
Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.I型胶原蛋白生物标志物在乳腺癌、肺癌、膀胱癌和前列腺癌骨转移诊断中的应用。与癌胚抗原(CEA)、糖类抗原15-3(CA 15-3)、前列腺特异抗原(PSA)及骨闪烁显像的比较。
J BUON. 2009 Jul-Sep;14(3):463-72.
3
Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.唑来膦酸治疗转移性乳腺癌时骨标志物测量用于监测反应的有效性。
Oncol Rep. 2013 Jul;30(1):441-7. doi: 10.3892/or.2013.2409. Epub 2013 Apr 22.
4
[Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].[血清Ⅰ型胶原吡啶交联羧基末端肽(ICTP)和人Ⅰ型前胶原羧基末端前肽(PICP)在骨转移诊断中的应用]
Kaku Igaku. 1996 Jan;33(1):77-84.
5
Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.血清I型胶原羧基末端肽(ICTP)以及I型前胶原羧基末端和氨基末端前肽(PICP、PINP)的浓度作为乳腺癌转移性骨病的标志物。
Anticancer Res. 1996 Jul-Aug;16(4B):2289-93.
6
Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.术前高I型胶原降解标志物ICTP反映晚期乳腺癌。
Anticancer Res. 1999 Sep-Oct;19(5C):4481-4.
7
Biochemical picture of bone metabolism in breast cancer patients with bone metastases.伴有骨转移的乳腺癌患者骨代谢的生化情况
Anticancer Res. 1995 Nov-Dec;15(6B):2871-5.
8
Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.骨闪烁显像与骨标志物在肺癌患者骨转移诊断中的比较。
Anticancer Res. 2004 Sep-Oct;24(5B):3193-201.
9
Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.血清I型前胶原羧基末端前肽和I型胶原吡啶啉交联羧基末端肽在前列腺癌患者中的临床应用价值
Jpn J Clin Oncol. 1996 Jun;26(3):157-63. doi: 10.1093/oxfordjournals.jjco.a023200.
10
[Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].[I型胶原相关物质作为前列腺癌骨转移标志物的研究,特别关注I型前胶原血清羧基末端前肽(PICP)、I型胶原交联羧基末端端肽(ICTP)及尿脱氧吡啶啉水平]
Nihon Hinyokika Gakkai Zasshi. 1998 Apr;89(4):484-91. doi: 10.5980/jpnjurol1989.89.484.

引用本文的文献

1
Methodology and applications of disease biomarker identification in human serum.人血清中疾病生物标志物鉴定的方法学与应用
Biomark Insights. 2007 Feb 14;2:21-43.
2
Do serum biomarkers really measure breast cancer?血清生物标志物真的能检测出乳腺癌吗?
BMC Cancer. 2009 May 28;9:164. doi: 10.1186/1471-2407-9-164.